FDA’s Diversity Action Plan: Questions, answers, and what we (don’t) know so far

By Laura DiAngelo, MPH

Last month, the FDA published a new draft guidance document on diversity action plans. While the new version of the guidance is greatly expanded as compared to an earlier version from 2022, it has left plenty of important questions unanswered. In this piece, AgencyIQ answers some of the most common questions we’ve received about the guidance – and raise a few of our own.

Fill out the form to read the full article.